Management of fungal infections following allogeneic stem cell transplantation.
Fungal infection remains an important complication in allogeneic stem cell transplantation (allo-SCT). Since the prognosis of fungal infection is poor, prophylaxis is critical for its management; owing to recent progression in allo-SCT management and widespread use of reduced-intensity regimens, the strategy of infectious prophylaxis has also changed. Various antifungals have recently been developed and applied to clinical use. A major change in antifungal management will probably occur in the next few years.
Narimatsu
Hiroto
H
Division of The Strategic Outcome Research Program for Cancer Control MHLW-commission, Japan Cancer Society, Yurakucho Center Bldg. (Mullion) 13F, 2-5-1, Yurakucho Chiyoda-ku Tokyo, 100-0006, Japan. hiroto-narimatsu@umin.net
Kami
Masahiro
M
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D001393:Azoles / Q000627:therapeutic use; D018890:Chemoprevention; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D054714:Echinocandins / Q000627:therapeutic use; D005658:Fungi / Q000145:classification / Q000472:pathogenicity; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control*; D011090:Polyenes / Q000627:therapeutic use; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014184:Transplantation, Homologous / Q000009:adverse effects*; D016896:Treatment Outcome
D000935:Antifungal Agents; D001393:Azoles; D054714:Echinocandins; D011090:Polyenes